Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • G-Quadruplexes Regulate TDP43 Aggregation and Toxicity in AL

    2026-05-16

    G-Quadruplexes Regulate TDP43 Aggregation and Toxicity in ALS Models

    Study Background and Research Question

    Trans-active response DNA-binding protein 43 kDa (TDP43) is a critical regulator of RNA metabolism, found predominantly in the nucleus but also localizing to the cytoplasm in both healthy and diseased cells. Pathological aggregation of TDP43 is a defining feature of amyotrophic lateral sclerosis (ALS) and several other neurodegenerative diseases, yet the molecular triggers behind TDP43 misfolding and toxicity remain unclear. Prior research has shown that TDP43 binds GU-rich sequences and G-quadruplexes (G4s)—four-stranded secondary structures formed in guanine-rich nucleic acids—which have recently been identified as key modulators of protein aggregation in stress contexts. The central question addressed by Oldani et al. is whether RNA G-quadruplexes (rG4s) can influence TDP43 phase behavior and cytotoxicity, potentially opening new avenues for therapeutic intervention in ALS and related disorders (Oldani et al., 2025).

    Key Innovation from the Reference Study

    The innovation of this study lies in its direct demonstration that both exogenous and small-molecule-stabilized G-quadruplexes modulate TDP43 condensation and toxicity in vitro and in multiple cell types. By linking the biophysical properties of G-quadruplexes to the cellular fate of TDP43, the authors provide strong evidence that targeting RNA secondary structures can influence protein aggregation pathways implicated in neurodegeneration (Oldani et al., 2025).

    Methods and Experimental Design Insights

    Oldani et al. employed a combination of biophysical assays, yeast genetics, and mammalian cell models to systematically dissect the impact of G-quadruplexes on TDP43. Key methodological highlights include:
    • In vitro aggregation assays: Recombinant eGFP-tagged TDP43 was incubated with synthetic DNA G-quadruplexes to assess effect on aggregation kinetics and morphology.
    • Yeast model (Saccharomyces cerevisiae): Expression of human TDP43 and treatment with exogenous G-quadruplex oligonucleotides; cell survival and TDP43 localization were quantified under these conditions.
    • HEK293T and NSC-34 cell studies: Human and mouse cell lines expressing TDP43 were exposed to small-molecule G-quadruplex stabilizers under proteostatic and oxidative stress. Condensation and cytotoxicity were measured by fluorescence microscopy and cell survival assays.
    • Co-localization analysis: The spatial relationship between G-quadruplexes and TDP43 aggregates was determined in stressed NSC-34 cells using imaging and quantitative co-localization metrics.
    The study design balanced in vitro mechanistic probing with disease-relevant cellular models to build a robust picture of G4-mediated modulation of TDP43.

    Core Findings and Why They Matter

    1. G-quadruplexes modulate TDP43 aggregation in vitro. Addition of synthetic DNA G-quadruplexes to purified TDP43 significantly altered its phase separation and aggregation behavior in biochemical assays, suggesting a direct chaperoning effect (Oldani et al., 2025).
    2. G-quadruplexes co-localize with TDP43 aggregates in stressed cells. In NSC-34 motor neuron-like cells, under stress, RNA G-quadruplexes and TDP43 condensates displayed significant spatial overlap, supporting the hypothesis that G4s are active participants in TDP43 phase transitions.
    3. Exogenous G-quadruplexes increase cellular tolerance for TDP43. Treatment of yeast expressing human TDP43 with G4 oligonucleotides increased cell survival and delayed cytotoxicity, indicating a protective effect of G4s on TDP43 toxicity.
    4. G-quadruplex binding ligands alleviate TDP43 condensation and cytotoxicity. In both yeast and mammalian cells, small molecules known to stabilize G-quadruplex structures (e.g., Pyridostatin and related compounds) reduced the formation of pathological TDP43 condensates and improved cell viability under stress. This effect was observed with both proteasomal inhibition and oxidative challenge, underscoring the broad relevance of G-quadruplex targeting (Oldani et al., 2025).
    These results demonstrate that G4s act as molecular modifiers of TDP43 behavior and cytotoxicity, providing a mechanistic link between RNA secondary structures and neurodegenerative disease pathology.

    Protocol Parameters

    • assay | 0–40 μM G-quadruplex ligand | TDP43 condensation, cytotoxicity assays | Matches concentration range validated for G4 stabilization and cellular studies | product_spec
    • assay | 72 hours exposure | mammalian cell models | Standard window for observing protein aggregation and cell viability | product_spec
    • assay | Use of G4-forming oligonucleotides | yeast and in vitro assays | Directly tests the impact of nucleic acid structure on TDP43 | paper
    • assay | Stress induction (proteasomal/oxidative) | HEK293T, NSC-34 | Models disease-relevant environmental triggers for TDP43 aggregation | paper
    • workflow | Storage at -20°C (stock solutions) | All cell-based assays | Ensures reagent stability, minimizes batch-to-batch variability | product_spec

    Comparison with Existing Internal Articles

    Several internal resources provide foundational guidance for G-quadruplex biology and experimental use of stabilizing compounds: The reference study by Oldani et al. extends these technical resources by providing direct experimental evidence that RNA (rather than DNA) G-quadruplex stabilization can modulate protein aggregation in models of ALS. This complements internal content which has so far focused more heavily on telomere biology and cancer cell growth inhibition.

    Limitations and Transferability

    While the study convincingly demonstrates a role for G-quadruplexes in modulating TDP43 aggregation and toxicity, several caveats should be noted:
    • Model system translation: Most experiments were performed in yeast, HEK293T, and NSC-34 cells. While these models provide valuable insight, their relevance to human neurons and in vivo disease remains to be validated (Oldani et al., 2025).
    • Specificity of small molecule ligands: While G-quadruplex binding compounds such as Pyridostatin are well-validated DNA G4 stabilizers, their selectivity for RNA G4s and off-target effects in cellular environments require further investigation (workflow_recommendation).
    • Mechanistic uncertainty: The exact molecular mechanism by which G4s modulate TDP43 condensation—whether by direct binding or via broader changes in RNA-protein interactions—remains to be elucidated.
    Thus, while these findings are highly promising for the field of neurodegenerative disease research, careful validation in more physiologically relevant models is necessary.

    Why this cross-domain matters, maturity, and limitations

    The bridge from cancer cell growth inhibition (where G-quadruplex stabilizers such as Pyridostatin have been extensively studied) to neurodegenerative disease models is supported by emerging literature, including the present study. This cross-domain application is enabled by the shared mechanistic foundation of G-quadruplex biology but is still in the early stages of translational maturity (Oldani et al., 2025; internal_article). Key limitations include differences in cellular context, nucleic acid targets (DNA vs. RNA), and the need for more nuanced assessment of compound specificity.

    Research Support Resources

    For researchers seeking to replicate or extend G-quadruplex stabilization studies, Pyridostatin (SKU A3742, APExBIO) is a widely used synthetic small molecule that selectively stabilizes G-quadruplex structures in vitro and in cells, with validated protocols for both telomere biology and emerging applications in protein aggregation and neurodegeneration (product_spec). For additional experimental strategies and troubleshooting insights, internal articles such as Pyridostatin: A G-Quadruplex DNA Structure Stabilizer for Research and Pyridostatin: Advancing G-Quadruplex Biology and Disease Research can provide further guidance.